{
    "id": 8761,
    "name": "megakaryocytic leukemia",
    "source": "DOID",
    "definition": "A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers. [url:http\\://medical-dictionary.thefreedictionary.com/megakaryocytic+leukemia]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "9009"
    ],
    "termId": "DOID:8761",
    "evidence": [
        {
            "id": 1428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cytosar-U (cytarabine) in an non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",
            "molecularProfile": {
                "id": 2519,
                "profileName": "GATA1 over exp"
            },
            "therapy": {
                "id": 712,
                "therapyName": "Cytarabine",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1278,
                    "pubMedId": 23874683,
                    "title": "Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23874683"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cerubidine (daunorubicin) in a non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",
            "molecularProfile": {
                "id": 2519,
                "profileName": "GATA1 over exp"
            },
            "therapy": {
                "id": 1006,
                "therapyName": "Daunorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1278,
                    "pubMedId": 23874683,
                    "title": "Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23874683"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3794,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a trisomy 21 cell line of acute megakaryocytic leukemia with DYRK1A over expression was sensitive to harmine in culture (PMID: 22354171).",
            "molecularProfile": {
                "id": 15328,
                "profileName": "DYRK1A over exp"
            },
            "therapy": {
                "id": 3324,
                "therapyName": "Harmine",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4156,
                    "pubMedId": 22354171,
                    "title": "Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22354171"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6078,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620).",
            "molecularProfile": {
                "id": 22437,
                "profileName": "GATA1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5284,
                    "pubMedId": 25266042,
                    "title": "Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25266042"
                },
                {
                    "id": 5285,
                    "pubMedId": 14636651,
                    "title": "Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14636651"
                },
                {
                    "id": 5286,
                    "pubMedId": 12586620,
                    "title": "GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12586620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KIT wild-type megakaryocytic leukemia cells were less sensitive to Ayvakit (avapritinib) compared to cells harboring KIT mutations in culture (PMID: 29093181).",
            "molecularProfile": {
                "id": 582,
                "profileName": "KIT wild-type"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10301,
                    "pubMedId": 29093181,
                    "title": "A precision therapy against cancers driven by KIT/PDGFRA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29093181"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a megakaryoblastic leukemia cell line expressing JAK2 V617F demonstrated inhibition of cell proliferation in culture when treated with Ropeginterferon (PMID: 30287855).",
            "molecularProfile": {
                "id": 591,
                "profileName": "JAK2 V617F"
            },
            "therapy": {
                "id": 8691,
                "therapyName": "Ropeginterferon",
                "synonyms": null
            },
            "indication": {
                "id": 8761,
                "name": "megakaryocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16080,
                    "pubMedId": 30287855,
                    "title": "Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30287855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02530619",
            "title": "Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        }
    ]
}